|MDACC Study No:||2010-0907 (clinicaltrials.gov NCT No: NCT01400503)|
|Title:||An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman’s Disease|
|Principal Investigator:||Luis E. Fayad|
|Treatment Agent:||CNTO 328|
|Study Description:||The goal of this clinical research study is to learn more about the long term |
safety of siltuximab in patients with multicentric Castleman's disease.
Researchers also want to learn if siltuximab can help to control multicentric
Siltuximab is an antibody that is designed to block the activity of IL-6 (a
protein found naturally in the body that can promote the growth of cancer
cells). By blocking IL-6, siltuximab may slow cancer growth.